That could move earlier if Phase 3 data is strong and Eli Lilly prioritises the Australian market submission, or it could push to 2028 if there are complications
Glutathione gip ci thin n hi ca da : Gp phn sn sinh Collagen trn da t gip cho ln da tr nn mn mng, ngn nga s xut hin ca np nhn trn da
He presented the results Sunday at the European Congress on Obesity in Malaga, Spain
Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)